{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:43:18Z","timestamp":1790790198051,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T00:00:00Z","timestamp":1567209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T00:00:00Z","timestamp":1567209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Auton Res"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s10286-019-00630-y","type":"journal-article","created":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T09:59:11Z","timestamp":1567245551000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: a systematic review"],"prefix":"10.1007","volume":"29","author":[{"given":"Alejandra","family":"Gonzalez-Duarte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio I.","family":"Vald\u00e9s-Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cant\u00fa-Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,31]]},"reference":[{"key":"630_CR1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","volume":"10","author":"V Plant\u00e9-Bourdeneuve","year":"2011","unstructured":"Plant\u00e9-Bourdeneuve V, Said G (2011) Familial amyloid polyneuropathy. Lancet Neurol 10:1086\u20131097","journal-title":"Lancet Neurol"},{"key":"630_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-018-0514-2","author":"A Gonzalez-Duarte","year":"2018","unstructured":"Gonzalez-Duarte A (2018) Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis). Clin Auton Res. \n                    https:\/\/doi.org\/10.1007\/s10286-018-0514-2","journal-title":"Clin Auton Res"},{"issue":"1","key":"630_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jns.12153","volume":"21","author":"I Conceicao","year":"2016","unstructured":"Conceicao I, Gonzalez-Duarte A, Obici L (2016) Red-flag symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 21(1):5\u20139","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"630_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13023-017-0726-x","volume":"13","author":"Y Sekijima","year":"2018","unstructured":"Sekijima Y, Ueda M, Koike H et al (2018) Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis 13(1):6. doi: \n                    https:\/\/doi.org\/10.1186\/s13023-017-0726-x","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"630_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1136\/jnnp.71.3.371","volume":"72","author":"IF Hussain","year":"2001","unstructured":"Hussain IF, Brady CM, Swinn MJ et al (2001) Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson\u00b4s disease and multiple system atrophy with observations on orthostatic hypotension. Neurol Neurosurg Psychiatr 72(3):371\u2013374","journal-title":"Neurol Neurosurg Psychiatr"},{"issue":"19","key":"630_CR6","first-page":"86","volume":"30","author":"Z Xin Zang","year":"2014","unstructured":"Xin Zang Z, Za Zhi X (2014) Cardiac amyloidosis presenting as recurrent syncope. Acta Cardiol Sin 30(19):86\u201389","journal-title":"Acta Cardiol Sin"},{"issue":"1","key":"630_CR7","first-page":"71","volume":"109","author":"Mesquita E Tinoco","year":"2017","unstructured":"Tinoco Mesquita E, Lagoeiro AJ, Vale C et al (2017) Cardiac amyloidosis and its new critical phenotype: heart failure with preserved ejection fraction. Arq Bras Cardiol 109(1):71\u201380","journal-title":"Arq Bras Cardiol"},{"key":"630_CR8","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.19102\/icrm.2018.090301","volume":"9","author":"RM John","year":"2018","unstructured":"John RM (2018) Arrythmias in cardiac amyloidosis. J Innov Card Rhythm Manag 9:3051\u20133057","journal-title":"J Innov Card Rhythm Manag"},{"issue":"7","key":"630_CR9","first-page":"e10000100","volume":"6","author":"A Liertati","year":"2009","unstructured":"Liertati A, Altman D, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Plos Med 6(7):e10000100","journal-title":"Plos Med"},{"issue":"1","key":"630_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/(SICI)1520-6777(1997)16:1<55::AID-NAU7>3.0.CO;2-D","volume":"16","author":"G Hita Villaplana","year":"1997","unstructured":"Hita Villaplana G, Hita Rosino E, L\u00f3pez Cubilana P et al (1997) Corino-andrade disease (familial amyloidotic polyneuropathy type I) in Spain: urological and andrological disorders. Neurourol Urodyn 16(1):55\u201361","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"630_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1600-0404.1997.tb00260.x","volume":"96","author":"M Alves","year":"1997","unstructured":"Alves M, Conceicao I, Luis ML (1997) Neurophysiological evaluation of sexual dysfunction in familial amyloidotic polyneuropathy Portuguese type. Acta Neurol Scand 96(3):163\u2013166","journal-title":"Acta Neurol Scand"},{"issue":"10","key":"630_CR12","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1111\/j.1572-0241.2003.07695.x","volume":"98","author":"Guri Mj","year":"2003","unstructured":"Mj Guri, H\u00f6genauer C, Santa Ana CA et al (2003) Rapid intestinal transit as a primary cause of severe chronic diarrhea in patients with amyloidosis. Am J Gastroenterol 98(10):2219\u20132225","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"630_CR13","first-page":"874","volume":"46","author":"S Ikeda","year":"2006","unstructured":"Ikeda S (2006) Autonomic dysfunction in FAP: its therapeutic effect by liver transplantation. Rinsho Shinkeigaku 46(11):874\u2013877","journal-title":"Rinsho Shinkeigaku"},{"issue":"3","key":"630_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.21332","volume":"40","author":"DH Kim","year":"2009","unstructured":"Kim DH, Zeldenrust SR, Low PA et al (2009) Quantitative sensation and autonomic test abnormalities in thrasnthyretin amyloidosis polyneuropathy. Muscle Nerve 40(3):363\u2013370","journal-title":"Muscle Nerve"},{"issue":"6","key":"630_CR15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.nmd.2016.03.006","volume":"26","author":"M Russo","year":"2016","unstructured":"Russo M, Vita GL, Stancanelli C et al (2016) Parenteral nutrition improves nutritional status, autonomic symtpoms and quality of life in transthyretin amyloid polyneuropathy. Neuromusc dis 26(6):374\u2013377","journal-title":"Neuromusc dis"},{"issue":"8","key":"630_CR16","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.clinph.2018.05.005","volume":"129","author":"JP Lefaucheur","year":"2018","unstructured":"Lefaucheur JP, Zouari HG, Gorram F et al (2018) The value of electrochemical skin conductance measuremewnt using Sudoscan in the assessment of patients with familial amyloid polyneuropathy. Clin Neurophysiol 129(8):1565\u20131569","journal-title":"Clin Neurophysiol"},{"issue":"1","key":"630_CR17","doi-asserted-by":"publisher","first-page":"94-e10","DOI":"10.1111\/ene.13774","volume":"26","author":"HG Zouari","year":"2019","unstructured":"Zouari HG, Ng Wing Tin S, Wahab A et al (2019) Assessment of autonomic innervation of the foot in familial amyloid polyneuropathy. Eur J Neurol 26(1):94-e10","journal-title":"Eur J Neurol"},{"issue":"Suppl 7","key":"630_CR18","first-page":"P05.067","volume":"80","author":"M Cardoso","year":"2013","unstructured":"Cardoso M, Coelho T, Mundayat R (2013) Overview of patient demographics and clinical characteristics in THAOS\u2014the trasthyretin amyloidosis outcome survey (P05.067). Neurology 80(Suppl 7):P05.067","journal-title":"Neurology"},{"issue":"3","key":"630_CR19","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/jns.12225","volume":"22","author":"F Barroso","year":"2017","unstructured":"Barroso F, Ando Y, Gonz\u00e1lez-Duarte A (2017) Autonomic symptoms in transthyretin amyloidosis: an analysis of symptomatic subjects from the\nTHAOS REgistry. 2017 Peripheral nerve society meeting July 8\u201312, 2017 Sitges, Barcelona, Spain. J Peripheral Nerv Syst 22(3):226\u2013414","journal-title":"J Peripheral Nerv Syst JPNS"},{"key":"630_CR20","first-page":"114","volume":"381","author":"A Gonz\u00e1lez-Duarte","year":"2018","unstructured":"Gonz\u00e1lez-Duarte A, Ba\u00f1uelos C, Garc\u00eda K et al (2018) Autonomic description in patients with very early TTR amyloidosis (Familial Amyloid Polyneuropathy) (P2.111). Neurology 381:114","journal-title":"Neurology"},{"key":"630_CR21","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.3233\/JND-150091","volume":"2","author":"A Mazzeo","year":"2015","unstructured":"Mazzeo A, Russo M, Di Bella G et al (2015) Transthyretin-related familial amyloid polyneuropathy (TTR-FAP): a single-center experience in Sicily, an Italian endemic area. J Neuromusc Dis 2:S39\u2013S48","journal-title":"J Neuromusc Dis"},{"issue":"4","key":"630_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3109\/13506129.2013.827110","volume":"20","author":"A Gonzalez-Duarte","year":"2013","unstructured":"Gonzalez-Duarte A, Lem-Carrillo M, Cardenas-Soto K (2013) Description of transthyretin S50A, S52P and G47A mutations in familial amyloidosis polyneuropathy. Amyloid 20(4):221\u2013225","journal-title":"Amyloid"},{"key":"630_CR23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1080\/13506129.2018.1503593","volume":"25","author":"M Waddington-Cruz","year":"2018","unstructured":"Waddington-Cruz M, Ackermann E, Polydefkis M et al (2018) Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial. Amyloid 25:180\u2013188","journal-title":"Amyloid"},{"issue":"1","key":"630_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/13506129.2012.674580","volume":"19","author":"H Koike","year":"2012","unstructured":"Koike H, Soubou G (2012) Late-onset familial amyloid polyneuropathy in Japan. Amyloid 19(1):55\u201357","journal-title":"Amyloid"},{"issue":"7","key":"630_CR25","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1212\/WNL.58.7.1001","volume":"58","author":"S Ikeda","year":"2001","unstructured":"Ikeda S, Nakazato M, Ando N et al (2001) Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 58(7):1001\u20131007","journal-title":"Neurology"},{"key":"630_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Salvi F (2013) Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 8:1\u201383","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"630_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12883-017-0948-5","volume":"17","author":"D Adams","year":"2017","unstructured":"Adams D, Suhr OB, Dyck PJ et al (2017) Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurol 17(1):181. doi:\n                    https:\/\/doi.org\/10.1186\/s12883-017-0948-5","journal-title":"BMC Neurol"},{"issue":"3","key":"630_CR28","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/mus.25257","volume":"55","author":"T Coelho","year":"2017","unstructured":"Coelho T, Vinik A, Vinik EJ et al (2017) Clinical measures in trasthyretin familial amyloid polyneuropathy. Muscle Nerve 55(3):323\u2013332","journal-title":"Muscle Nerve"},{"key":"630_CR29","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, da Silva AM et al (2012) Tafamidis for transthyretin familial amyloid polyneuropathy. A randomized, controlled trial. Neurology 79:785\u2013792","journal-title":"Neurology"},{"issue":"1","key":"630_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarrte A, Oriordan WD et al (2018) Patisiran, a RNIi therapeutic for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11\u201321","journal-title":"N Engl J Med"},{"issue":"1","key":"630_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"M Benson","year":"2018","unstructured":"Benson M, Waddington-Cruz M, Berk J et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22\u201331","journal-title":"N Engl J Med"},{"issue":"5","key":"630_CR32","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/WCO.0000000000000244","volume":"28","author":"R Freeman","year":"2015","unstructured":"Freeman R, Barroso F (2015) Recent advances in familial amyloid polyneuropathy. Curr Opin Neurol 28(5):494\u2013499","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"630_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/13506129.2018.1434140","volume":"25","author":"U Wiklund","year":"2018","unstructured":"Wiklund U, Kadknodaee A, Andersson K et al (2018) Normal scores of deep breathing tests: beware of dysrhythmia in transthyretin amyloidosis. Amyloid 25(1):54\u201361","journal-title":"Amyloid"},{"issue":"4","key":"630_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/jns.12290","volume":"23","author":"M Mauermann","year":"2018","unstructured":"Mauermann M, Adams D, Gonz\u00e1lez-Duarte A (2018) Impact of patisiran on autonomic neuropathy in hereditary transthyretin-mediatedamyloidosis patients. Peripheral nerve society annual meeting 21\u201325 July, 2018 Baltimore. Maryland. JPNS 23(4):249\u2013408","journal-title":"Maryland. JPNS"},{"issue":"Suppl. 1","key":"630_CR35","first-page":"775","volume":"19","author":"OB Suhr","year":"2012","unstructured":"Suhr OB, Concei\u00e7\u00e3o I, Karayal O et al (2012) Nutritional status and autonomic function in clinical trials of tafamidis for transthyretin familial polyneuropathy. Eur J Neurol 19[Suppl 1]:775","journal-title":"Eur J Neurol"}],"container-title":["Clinical Autonomic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-019-00630-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10286-019-00630-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-019-00630-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T23:11:07Z","timestamp":1598742667000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10286-019-00630-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,31]]},"references-count":35,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["630"],"URL":"https:\/\/doi.org\/10.1007\/s10286-019-00630-y","relation":{},"ISSN":["0959-9851","1619-1560"],"issn-type":[{"value":"0959-9851","type":"print"},{"value":"1619-1560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,31]]},"assertion":[{"value":"5 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A. Gonzalez-Duarte has been advisor to and investigator in clinical trials funded by Pfizer and Alnylam. S.I. Vald\u00e9s-Ferrer and C. Cant\u00fa-Brito have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}